tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.

abstract：:Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

journal_title：Leukemia & lymphoma

authors： Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

更新日期：2006-10-01 00:00:00

abstract：:Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

journal_title：Leukemia & lymphoma

authors： Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

更新日期：2010-12-01 00:00:00

abstract：:Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We desig...

journal_title：Leukemia & lymphoma

authors： Shin SH,Kim YJ,Lee D,Cho D,Ko YH,Cho J,Park WY,Park D,Kim SJ,Kim WS

更新日期：2019-09-01 00:00:00

abstract：:Allogeneic stem-cell transplantation (SCT) is potentially curative treatment for AML and MDS. New conditioning regimens are continuously explored trying to reduce toxicity while maintaining antileukemia effect. Treosulfan is an alkylating agent with in vitro cytotoxicity against leukemia as well as myeloablative and i...

journal_title：Leukemia & lymphoma

authors： Shimoni A,Hardan I,Shem-Tov N,Rand A,Yerushalmi R,Nagler A

更新日期：2007-12-01 00:00:00

abstract：:We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

journal_title：Leukemia & lymphoma

authors： Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

更新日期：2010-07-01 00:00:00

abstract：:Abstract Increasing manganese superoxide dismutase (MnSOD) expression can suppress the malignant phenotype in various cancer cell lines and suppress tumor formation in xenograft and transgenic mouse models. A mimic of manganese superoxide dismutase (MnSODm), synthesized by a chemical method, has been shown to possess ...

journal_title：Leukemia & lymphoma

authors： Wang YH,Xu XJ,Zhang LF,Li HL

更新日期：2014-05-01 00:00:00

abstract：:A 31-year-old woman with acute myeloblastic leukemia (AML) underwent allogeneic peripheral blood stem cell transplant (PBSCT). On day +274 following transplantation, the patient had severe chest pain, high-grade fever, and general fatigue. Electrocardiographic examination revealed ST segment elevation, and echocardiog...

journal_title：Leukemia & lymphoma

authors： Aoyama Y,Nakao Y,Ohta K,Sakai T,Nakamae H,Yamamura R,Yamane T,Hino M

更新日期：2004-02-01 00:00:00

abstract：:Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

journal_title：Leukemia & lymphoma

authors： Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

更新日期：2012-11-01 00:00:00

abstract：:HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

journal_title：Leukemia & lymphoma

authors： Burke LP,Kukoly CA

更新日期：2008-02-01 00:00:00

abstract：:We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

journal_title：Leukemia & lymphoma

authors： McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

更新日期：1998-06-01 00:00:00

abstract：:We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (wh...

journal_title：Leukemia & lymphoma

authors： Middeke JM,Teipel R,Röllig C,Stasik S,Zebisch A,Sill H,Kramer M,Scholl S,Hochhaus A,Jost E,Brümmendorf TH,Naumann R,Steffen B,Serve H,Altmann H,Kunzmann V,Einsele H,Parmentier S,Schaich M,Burchert A,Neubauer A,S

更新日期：2021-01-05 00:00:00

abstract：:Therapy-related changes of the bone marrow fiber content remain a controversial issue in hematopathology. This conflict of opinion firstly depends on difficulties to determine the quantity of fibers exactly (semiquantitative grading, morphometry, reference to cellularity). Secondly, the appropriate selection of patien...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM

更新日期：2001-09-01 00:00:00

abstract：:Several techniques developed in recent years provide us with the capability to detect sub-microscopic leukemia during remission. Quantitative polymerase chain reaction (PCR) is thus far the most sensitive assay that is applicable in most patients with acute lymphoblastic leukemia (ALL) of childhood. However, false-pos...

journal_title：Leukemia & lymphoma

authors： Estrov Z,Freedman MH

更新日期：1999-03-01 00:00:00

abstract：:The transduction of exogenous hepatocyte growth factor (HGF) genes to spleen T lymphocytes and the immune effects of syngeneic spleen graft on spleen lymphoma cells were studied in LEW/Sea rats. Three different systems were designed. (1) Six female rats and six male rats received irradiated spleen graft and were follo...

journal_title：Leukemia & lymphoma

authors： Nakatsuji T

更新日期：2003-01-01 00:00:00

abstract：:The prognostic significance of immunophenotype and other features including sex, age, anaemia, WBC, FAB type, and PAS staining were analysed in a group of 389 children newly diagnosed as acute lymphoblastic leukemia (ALL) and treated according to the BFM 1981/1983 protocol. The CR rate was higher (82-94%) in immunophe...

journal_title：Leukemia & lymphoma

authors： Holowiecki J,Koehler M,Zintl Z,Kardos G,Lutz D,Krzemien S,Rewesz T,Brugiatelli M,Callea V,Kachel L

更新日期：1992-06-01 00:00:00

abstract：:We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

journal_title：Leukemia & lymphoma

authors： Grigg AP

更新日期：2001-08-01 00:00:00

abstract：:B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

journal_title：Leukemia & lymphoma

authors： Jabbar SA,Hoffbrand AV,Wickremasinghe RG

更新日期：1995-06-01 00:00:00

abstract：:According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hematological malignan...

journal_title：Leukemia & lymphoma

authors： Park MJ,Park YH,Ahn HJ,Choi W,Paik KH,Kim JM,Chang YH,Ryoo BY,Yang SH

更新日期：2005-08-01 00:00:00

abstract：:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1993-01-01 00:00:00

abstract：:Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly. The Philadelphia positive (Ph+) clone was however still...

journal_title：Leukemia & lymphoma

authors： Michaeli J,Fibach E,Rachmilewitz EA

更新日期：1993-10-01 00:00:00

abstract：:Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing ...

journal_title：Leukemia & lymphoma

authors： Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

更新日期：2017-03-01 00:00:00

abstract：:Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

journal_title：Leukemia & lymphoma

authors： Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

更新日期：2010-06-01 00:00:00

abstract：:Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to R...

journal_title：Leukemia & lymphoma

authors： Janikova A,Bortlicek Z,Campr V,Kopalova N,Benesova K,Hamouzova J,Belada D,Prochazka V,Pytlik R,Vokurka S,Pirnos J,Duras J,Mocikova H,Mayer J,Trneny M

更新日期：2016-05-01 00:00:00

abstract：:Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

journal_title：Leukemia & lymphoma

authors： Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

更新日期：2019-10-01 00:00:00

abstract：:The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...

journal_title：Leukemia & lymphoma

authors： Poiré X,Moser BK,Gallagher RE,Laumann K,Bloomfield CD,Powell BL,Koval G,Gulati K,Holowka N,Larson RA,Tallman MS,Appelbaum FR,Sher D,Willman C,Paietta E,Stock W

更新日期：2014-07-01 00:00:00

abstract：:The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

journal_title：Leukemia & lymphoma

authors： Brown JR

更新日期：2010-08-01 00:00:00

abstract：:The incidence of central nervous system (CNS) involvement and effects of therapy were reviewed in 42 consecutive pediatric patients with acute nonlymphocytic leukemia (ANLL). The morphology of ileukemic cells was considered M1 in 13, M2 in 7, M3 in 5, M4 in 8, and M5 in 9. Two patients with M5 morphology presented wit...

journal_title：Leukemia & lymphoma

authors： Barrios N,Tebbi CK,Freeman AI

更新日期：1990-01-01 00:00:00

abstract：:Systemic mast cell disease (SMCD) has a highly variable clinical expression and course. That SMCD is associated with hematologic disorders has been widely described. We report an unusual case of systemic mast cell disease and concurrent chronic myelomonocytic leukemia in a 60 year old male. ...

journal_title：Leukemia & lymphoma

authors： Smith JD,Lazarchick J

更新日期：1999-01-01 00:00:00

abstract：:A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

journal_title：Leukemia & lymphoma

authors： Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

更新日期：2007-07-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00